Pricing Log in Create free account

Prothena Corporation plc (PRTA) vs Relmada Therapeutics, Inc. (RLMD)

Prothena Corporation plc and Relmada Therapeutics, Inc. are both Biotechnology companies. Prothena Corporation plc and Relmada Therapeutics, Inc. are of similar size ($455.5M and $421.5M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −80.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Prothena Corporation plc leads on 7 and Relmada Therapeutics, Inc. on 5.

Valuation

Metric PRTA RLMD Biotechnology median
P/E n/m n/m 10.64
P/S 7.89 n/m 9.59
P/B 1.50 2.32 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 2.60 n/m 9.45
Earnings yield (10.06%) (22.37%) (34.69%)
Free cash flow yield (14.13%) (26.54%) (24.02%)

Profitability

Metric PRTA RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.59%
Operating margin (101.80%) 0.00% 0.00%
Net margin (80.67%) 0.00% 0.00%
Free cash flow margin (111.49%) 0.00% 0.00%
Return on equity (14.39%) (55.66%) (51.96%)
Return on assets (12.54%) (51.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PRTA RLMD Biotechnology median
Revenue growth (TTM) 427.32% — 4.59%
EPS growth (last fiscal year) (99.56%) 45.28% 29.88%
Revenue growth, 5-year CAGR 62.56% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRTA RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 25.05 29.52 4.86
Net debt to EBITDA 1.46 1.57 1.01

Dividend

Metric PRTA RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric PRTA RLMD Biotechnology median
Market cap 421.47m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack